Iridex Adds EndoProbe® Handpieces to EyeProGPO Product Offering

Rhea-AI Summary

Iridex (Nasdaq: IRIX) expanded its partnership with ophthalmology-focused group purchasing organization EyeProGPO by adding Iridex’s EndoProbe® Handpieces to the EyeProGPO product offering. More than 4,300 EyeProGPO members now gain access to preferred pricing on these single-use vitreoretinal laser delivery devices.

The addition complements Iridex’s existing EyeProGPO portfolio, which already includes PASCAL®, IQ 532®, IQ 577®, OcuLight® TX, Cyclo G6® laser consoles and MicroPulse P3®, G-Probe®, and G-Probe Illuminate® devices. According to Iridex, the expanded agreement is intended to broaden member access to its retina laser systems and support ophthalmic providers with a wider range of EndoProbe models and gauges.

News Market Reaction – IRIX

-0.94%

-0.94% Session close to close

In the Jul 20 session, IRIX declined 0.94%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

Insider context reported Net Buying across 6 transactions during the analyzed period. That activity ...

Analysis

Insider context reported Net Buying across 6 transactions during the analyzed period. That activity provides a supportive ownership reference for this product-access expansion; execution and conversion of member access into business remain the relevant risks.

Key Figures

EyeProGPO members: more than 4,300 members Handpiece gauge configurations: 20G, 23G, 25G, 27G, and 30G

2 metrics

EyeProGPO members more than 4,300 members Members receiving preferred pricing access

Handpiece gauge configurations 20G, 23G, 25G, 27G, and 30G EndoProbe portfolio configurations

Historical Context

5 past events · Latest: Jun 09 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 09	Conference presentation	Neutral	+0.9%	Management scheduled to present at the Planet MicroCap Las Vegas conference
May 19	Quarterly earnings	Negative	-4.8%	Q1 revenue declined while cash decreased and the company reported a net loss
May 05	Earnings date notice	Neutral	-0.9%	Company scheduled its first-quarter financial results release and conference call
Apr 07	Partnership announcement	Positive	+0.0%	EyeProGPO agreement expanded preferred access to Iridex retina laser technology
Mar 26	Annual earnings	Positive	-26.7%	Full-year revenue grew and adjusted EBITDA turned positive despite delivery disruptions

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Historical reactions were mixed, with the prior EyeProGPO partnership producing a 0% move and the Q1 earnings decline aligning with a negative reaction.

Key Terms

vitreoretinal, fiber-optic, diabetic macular edema

3 terms

vitreoretinal medical

"preferred access to Iridex technologies used in vitreoretinal laser procedures"

Relating to the vitreous (the clear, gel-like substance filling the eye) and the retina (the light-sensitive layer at the back of the eye). Investors watch vitreoretinal treatments, devices and drugs because they target serious vision conditions; progress in clinical trials, approvals, or new surgical tools can change a medical company’s sales prospects and valuation much like a breakthrough engine or sensor can transform a carmaker’s market position.

fiber-optic technical

"continuous fiber-optic angle adjustment to support access to the peripheral retina"

Fiber-optic describes cables and systems that send information as pulses of light through very thin strands of glass or plastic, rather than as electrical signals through metal wires. For investors it matters because fiber-optic networks support much higher speeds, longer distances and lower delay—like replacing a slow dirt road with a high-speed highway—so companies that build, own or use fiber can gain cost advantages, enable new services and generate steadier cash flows.

diabetic macular edema medical

"treatment of glaucoma and diabetic macular edema (DME)"

Diabetic macular edema is an eye condition in which fluid leaks into and swells the macula, the part of the retina used for sharp, central vision, often as a complication of diabetes. For investors it matters because it drives demand for medicines, medical devices and eye-care services, influences clinical trial and regulatory outcomes, and can affect healthcare costs and revenue forecasts—think of the macula as the camera’s central lens that becomes blurred when it soaks up excess fluid.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MOUNTAIN VIEW, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced the expansion of its EyeProGPO product offering to include the Company’s line of EndoProbe^® Handpieces.

Through the agreement, more than 4,300 EyeProGPO members will have access to preferred pricing on Iridex EndoProbe Handpieces, expanding the value Iridex provides to ophthalmology practices, ambulatory surgery centers, and hospitals across the United States. The addition builds on Iridex’s existing EyeProGPO product offering, which includes the Iridex PASCAL^® laser platform, IQ 532^® and IQ 577^® Laser Consoles, OcuLight^® TX Laser Console, Cyclo G6^® Laser Console, and the MicroPulse P3^®, G-Probe^®, and G-Probe Illuminate^® delivery devices.

Iridex EndoProbe Handpieces are single-use devices indicated for use with Iridex laser consoles for the treatment of retinal disorders in adult patients. The EndoProbe portfolio includes straight, angled, stepped-angled, illuminating, and adjustable models, with configurations available in 20G, 23G, and 25G, and select stepped designs that taper to 27G and 30G.

Illuminating models combine white-light illumination with laser delivery in a single handpiece, allowing simultaneous use of additional instruments. Adjustable models provide continuous fiber-optic angle adjustment to support access to the peripheral retina.

"We are proud to partner with Iridex to offer their EndoProbe Handpieces to our members," said Phil Meyer, CEO of EyeProGPO, LLC. "This partnership underscores our strong commitment to working with our outstanding vendors while providing our members with access to the latest advancements in eye care technology, empowering them to deliver the highest quality patient care."

The expanded product offering is designed to provide EyeProGPO members with preferred access to Iridex technologies used in vitreoretinal laser procedures. By adding EndoProbe Handpieces to the existing contract, Iridex and EyeProGPO further strengthen their collaboration to provide EyeProGPO members with expanded access to the Iridex retina laser portfolio.

“We are pleased to add Iridex EndoProbe Handpieces to our EyeProGPO product offering, giving members broader access to our retina laser systems and delivery devices,” said Patrick Mercer, President and CEO of Iridex. “This addition reflects Iridex’s continued commitment to supporting retina specialists and ophthalmic providers with reliable technologies that help deliver value in vitreoretinal laser treatment.”

About EyeProGPO
EyeProGPO is an ophthalmology-focused group purchasing organization dedicated to helping ophthalmology practices, ambulatory surgery centers, and hospitals by providing access to cost-effective products and services and improving operational efficiency. With over 4,300 members, EyeProGPO harnesses collective purchasing power to deliver value on ophthalmic supplies, pharmaceuticals, intraocular lenses, capital equipment, and more. Focusing on quality, innovation, and value, EyeProGPO helps its members deliver the best possible patient care.

About Iridex Corporation
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, which include capital equipment and consumable probes for the ophthalmology market. The Company’s proprietary MicroPulse^® technology delivers the therapeutic benefits of laser treatment while minimizing tissue damage, offering a safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com.

MicroPulse^®, Iridex PASCAL^®, IQ 532^®, IQ 577^®, OcuLight^® TX, Cyclo G6^®, MicroPulse P3^®, G-Probe^®, and G-Probe Illuminate^® are a registered trademark of Iridex Corporation, Inc. in the United States, Europe, and other jurisdictions.

Iridex Media Contact
Joan Stauffer
jstauffer@iridex.com

Investor Relations Contact
Philip Taylor
investors@iridex.com

FAQ

What did Iridex (NASDAQ: IRIX) announce about EyeProGPO on July 20, 2026?

Iridex announced that its EndoProbe handpieces were added to the EyeProGPO product offering. According to Iridex, this expansion gives EyeProGPO’s more than 4,300 members preferred pricing and broader access to its retina laser delivery devices used in vitreoretinal procedures across the United States.

How many EyeProGPO members gain access to Iridex EndoProbe handpieces under the new agreement?

More than 4,300 EyeProGPO members gain access to Iridex EndoProbe handpieces. According to Iridex, these members, including ophthalmology practices, ambulatory surgery centers, and hospitals, can now obtain EndoProbe products at preferred pricing as part of the expanded group purchasing organization contract.

What are Iridex EndoProbe handpieces and how are they used in retinal treatment?

Iridex EndoProbe handpieces are single-use laser delivery devices for treating retinal disorders in adult patients. According to Iridex, they are used with Iridex laser consoles and offered in straight, angled, stepped-angled, illuminating, and adjustable models with multiple gauge configurations for vitreoretinal procedures.

Which Iridex products are already included in the EyeProGPO offering before adding EndoProbe handpieces?

EyeProGPO already offered several Iridex laser systems and delivery devices before adding EndoProbe. According to Iridex, the existing portfolio includes the PASCAL laser platform, IQ 532 and IQ 577 consoles, OcuLight TX, Cyclo G6, and MicroPulse P3, G-Probe, and G-Probe Illuminate devices.

How could the EyeProGPO agreement expansion affect access to Iridex retina laser technology?

The expansion is intended to broaden EyeProGPO members’ access to Iridex retina laser technology. According to Iridex, adding EndoProbe handpieces to the contract strengthens collaboration with EyeProGPO and gives members preferred access to a wider range of retina laser systems and consumable delivery devices.

What benefits do illuminating and adjustable Iridex EndoProbe models provide to eye surgeons?

Illuminating EndoProbe models combine white-light illumination and laser in a single handpiece. According to Iridex, this enables simultaneous use of additional instruments, while adjustable models provide continuous fiber-optic angle adjustment to improve access to the peripheral retina during vitreoretinal laser procedures.